Hydrocortisone with neomycin and polymyxin B
Brand names: Otosporin
A compound topical preparation combining the corticosteroid hydrocortisone with the antibiotics neomycin and polymyxin B sulfate, used for infected inflammatory conditions of the ear or eye.
Adult dose
Paediatric dose
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Known or suspected perforation of the tympanic membrane
- Allergic hypersensitivity to any of the components of the preparation, or to cross-sensitising substances such as framycetin, kanamycin, gentamicin and other related antibiotics
- Presence of untreated viral, fungal and tubercular infections
- Not recommended in neonates and infants (up to 3 years) - a possibility of increased absorption exists in very young children; absorption by immature skin may be enhanced and renal function may be immature
- Use in large quantities, or on large areas, for prolonged periods is not recommended in circumstances where significant systemic absorption may occur, because of the known ototoxic and nephrotoxic potential of neomycin sulphate
- Not recommended in pregnancy or lactation (section 4.6)
Side effects
- Allergic hypersensitivity to neomycin following topical use - may manifest as an eczematous exacerbation with reddening, scaling, swelling and itching, or as failure of the lesion to heal. Incidence in the general population is low but is increased in venous stasis eczema and ulceration and in chronic otitis externa
- Allergic hypersensitivity reactions to topical polymyxin B sulphate and hydrocortisone are rare
- Stinging and burning - occasionally reported when the drops gained access to the middle ear
- Rare (post-marketing): application site hypersensitivity; headache; application site reaction including pain, irritation, oedema, burning sensation and rash
- Rare (post-marketing), skin and subcutaneous tissue: local exfoliative dermatitis, skin atrophy, telangiectasia, striae, exacerbation of underlying skin conditions including eczema
- Systemic risks after significant absorption (section 4.4): irreversible ototoxicity from neomycin; nephrotoxic potential of neomycin and polymyxin B sulphate; neurotoxic potential of polymyxin B sulphate; potential suppression of the pituitary-adrenal axis from the corticosteroid
Monitoring
- Review at 7 days - treatment should not be continued beyond 7 days without medical supervision, nor beyond seven days in the absence of clinical improvement
- Renal function - caution and dose reduction where renal function is reduced, because plasma clearance of neomycin is decreased and prolonged unsupervised use may lead to irreversible partial or total deafness, especially in the elderly and in patients with impaired renal function
- Watch for delayed hypersensitivity to corticosteroids, skin sensitisation and emergence of resistant organisms on prolonged use
- Discontinue immediately and investigate further if prolonged or significant diarrhoea or abdominal cramps occur (pseudomembranous colitis has been reported with antibiotics, although this is unlikely with topical application)
- Avoid use in the immediate pre- and post-operative period - neomycin may rarely cause neuromuscular block and potentiates skeletal muscle relaxants, which may cause respiratory depression and arrest
- Increased risk of ototoxicity with aminoglycosides in patients with mitochondrial mutations, particularly m.1555A>G, sometimes with a maternal history of deafness and/or mitochondrial mutation
Clinical monograph
How it works
Neomycin (an aminoglycoside) and polymyxin B provide complementary antibacterial cover against Gram-positive and Gram-negative organisms, while hydrocortisone reduces local inflammation.
Prescribing in practice
- Avoid use in the ear when the tympanic membrane is perforated, as topical neomycin (an aminoglycoside) carries a risk of ototoxicity in the middle ear.
- Neomycin is a common contact sensitiser, so discontinue if local hypersensitivity develops.
- Reserve for short courses and reassess if there is no improvement to limit sensitisation and superinfection.
Monitoring
Monitor for clinical improvement and for any local hypersensitivity or, with ear use, hearing disturbance during treatment.
Counselling the patient
- Use only at the affected site and complete the short course as directed.
- Stop and seek advice if you develop a rash, itching or, with ear use, hearing changes or dizziness.
- Tell the clinician if your eardrum may be perforated before using drops in the ear.
Evidence & guidelines
Combined antibiotic-corticosteroid topical preparations are established for infected otitis externa and external eye infection, used cautiously per UK guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steroid Dose Equivalence · Medications
- Adrenal Insufficiency Assessment · Adrenal
- Adrenal Crisis Risk Score · Adrenal Disorders
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Acute Otitis Media — Antibiotic or Observation (AAP 2013) · Otitis Media
- Lille Model (Steroid Response in Alcoholic Hepatitis) · Alcoholic Liver Disease
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020